Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopa Iyer

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Cancer Discovery|June 18, 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyHikmat Al-Ahmadie, Gopa Iyer, Marcel Hohl, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Nature|November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitorDejan Juric, Pau Castel, Malachi Griffith, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2024
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic ImplicationsDilara Akbulut, Karissa Whiting, Min-Yuen Teo, et al.
Nature Communications|December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancerZiyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|August 18, 2015
Genomic Characterization of Upper Tract Urothelial CarcinomaJohn P Sfakianos, Eugene K Cha, Gopa Iyer, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Cancer Discovery|June 18, 2014
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapyHikmat Al-Ahmadie, Gopa Iyer, Marcel Hohl, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian CancerRachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Nature|November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitorDejan Juric, Pau Castel, Malachi Griffith, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2024
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic ImplicationsDilara Akbulut, Karissa Whiting, Min-Yuen Teo, et al.
Nature Communications|December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancerZiyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|August 18, 2015
Genomic Characterization of Upper Tract Urothelial CarcinomaJohn P Sfakianos, Eugene K Cha, Gopa Iyer, et al.
Pageof 14